MDCT assessment of CAD in type-2 XXXX subjects with @entity3949 : the role of Charcot neuro-arthropathy.

@entity1 @entity6 @entity3949 @entity4148 @entity460 @entity746 @entity850
OBJECTIVES: To compare the CACS and CAD severity assessed by MDCT in neuropathic type-2 @entity6 @entity1 with and without @entity746 ( @entity746 ). METHODS: Thirty-four @entity746 asymptomatic- @entity1 and 36 asymptomatic- @entity1 with @entity3949 ( @entity3949 ) without @entity746 underwent MDCT to assess CACS and severity of CAD. @entity1 were classified as positive for significant CAD in presence of at least one @entity850 >50 % on MDCT-coronary-angiography (MDCT-CA). Groups were matched for age, sex and traditional CAD risk-factors. The coronary-angiography (CA) was performed in all @entity1 with at least a significant @entity850 detected by MDCT-CA, both as reference and eventually as treatment. RESULTS: @entity746 @entity1 showed higher rates of significant CAD in comparison with @entity3949 subjects [p   <   0.001], while non-significant differences were observed in CACS (p   =   0.980). No significant differences were also observed in CACS distribution in all subjects for @entity850 >= /<50 % (p   =   0.814), as well as in both groups (p   =   0.661 and 0.559, respectively). The MDCT-CA showed an overall diagnostic-accuracy for significant CAD of 87%. CONCLUSIONS: These preliminary data suggest that @entity746 - @entity1 have a higher prevalence of severe CAD in comparison with @entity3949 - @entity1 , while coronary plaques do not exhibit an increased amount of @entity460 . MDCT may be helpful to assess the CV risk in such asymptomatic type-2- @entity6 @entity1 with @entity4148 . KEY POINTS: Type 2- @entity6 - @entity1 with @entity746 result having more severe coronary artery plaque-burden. MDCT-CA may stratify the CV risk in type 2- @entity6 - @entity1 with @entity746 . Adequate diagnostic is mandatory for optimal management of type 2- @entity6 - @entity1 with @entity746 .
